April 10-15 Marks the First Part of the AARC Annual Meeting
The 2021 Annual Meeting of the American Association for Cancer Research is being held as a virtual event this year and is scheduled in two parts. The first part is
Precision Engineering GPCR-Targeted Therapeutics
Orion Biotechnology is a clinical stage biotechnology company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases.
A Break Through Science & Technology Platform
We precision-engineer natural peptide and protein analogs that bind to GPCR targets with both enhanced potency and tailored signaling activity. This novel scientific approach is enabled by Orion’s proprietary drug discovery platform and has produced a growing pipeline of drug candidates that effectively target GPCRs implicated across therapeutic areas of high unmet need.
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a chemokine analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Neuroinflammation and HIV.
Recognized
Leadership
Previous
Next
Second Part of the AACR Annual Meeting to be held May 17-21
You can find out more by visiting their site and going to their on-line meeting planner.
We’re Looking Forward to the ASCO 2021 Annual Meeting
The 2021 Annual Meeting of ASCO is to be held From June 4th to 8th. Again this year it will be a ‘virtual’ event.
Robin Offord (1940 – 2021)
March 17, 2021
A brilliant scientist, determined colleague and trusted friend. It is with great sadness that we share news of the passing of our friend Robin Offord. Robin played an important
Orion presented the Results of our Successful Phase 1 Clinical Trial at the HIV Research for Prevention Conference
January 29, 2021
Ottawa, Canada January 27, 2021: Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of
Orion Biotechnology Project Awarded Grant to Advance Drug Discovery
January 14, 2021
Genève SWITZERLAND, Jan 14, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that its drug discovery project was
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
